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Abstract
Background: Hypercholesterolemia is a major classic risk factor for cardiovascular disease; however, there are 35%-
40% cases of cardiovascular where patients have normal cholesterol levels. Lp-PLA2 is an enzyme that is produced and 
secreted by macrophages as a response to the lipid peroxide formation, especially the platelet activating factor compound 
and phosphocholine peroxide. Lp-PLA2 has been correlated with classic risk factor of cardiovascular disease, although that 
correlation with number of foam cell at early stage of atherosclerosis is not clear yet. This study aims to determine the lipid 
profiles, oxidation stress markers and Lp-PLA2 levels at three different initial atherogenesis levels.
Methods: This study observed the change of Lp-PLA2, F2-Isp, MDA, TC, LDL, HDL levels in rat serum at three different 
levels of early atherogenesis; they were Ath-I, Ath-II and Ath-III made on the number of foam cells. The number of cells 
was observed in all aortic cross sectional surfaces, using the Oil-Red-O staining. The LDL-C content was measured using 
the Fiedwall formula, whereas the MDA content was measure by using TBA-test. The observation of F2-isoprostane and 
Lp-PLA2 were exemplified by the procedure of Elisa’s. 
Results: The one way ANOVA test results between the three initial levels of atherosclerosis showed no significant 
differences in all lipid profiles both in serum and stress oxidation markers. However, the LSD test results projected 
significant differences in LDL levels in Ath-I compared to others. There was a significant difference (p<0.01) in the serum 
of Lp-PLA2 content. The LSD test results displayed a significant increase in Lp-PLA2 enzyme levels since the Ath-II stage.
Conclussion: The elevated levels of Lp-PLA2 also increased the atherogenecity of LDL, due to the increased inflammation, 
stress oxidation and elevated levels of Lp-PLA2, which were interconnected with proatherogenic loops.
(Indonesian J Cardiol. 2019:40:282-289)
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Introduction
The process of atherogenesis begins with the formation of foam cells at the layer of sub-intima blood vessel walls. Atherosclerosis is the main cause of morbidity and mortality 
in the developing countries and becomes the primary 
etiology of cardio vascular diseases (CVD) such as 
coronary heart Disease (CHD), coronary arterial disease 
(CAD) dan cerebro vascular disease. Most CHDs 
are in the form of heart attack and most ischemia 
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cases occurring in the brain are secondary effects of 
atherosclerosis1,2.
 Atherosclerosis has many risk factors, among others: 
old age, smoking habit, obesity, hyper cholesterol, 
diabetes and high blood pressure.  Hyper cholesterol 
is the main classical risk factor of atherosclerosis4 in 
addition to the age factor2, since 30-40% part of the 
atherosclerosis plaque is made from crystal cholesterol, 
ether cholesterol and lipid peroxide3,5. Oxidized Low 
Density Lipoprotein (oxLDL) instead of native Low 
Density Lipoprotein (nLDL) plays a major role in 
developing atherosclerosis from the early to the advanced 
stages, where an oxLDL plasma is expected to be able 
to be used as the marker in diagnosing atherosclerosis6. 
In contracts, a controversy has been identified. 
Hyper cholesterols, which was the main risk factor of 
atherosclerosis with the data in the field showing that 
50% patients with atherosclerosis complication such 
as myocardial infarction did not have the classical risk 
factor7,8 and in 35-40% of all CHD cases, the patients 
turned out showing that the total cholesterol content 
to be normal4,9. Therefore, a study on nonconventional 
biomarkers which mostly are found in serum but are 
closely related to the process of atherogenesis, especially 
at early stages that may improve proterogenic effects of 
LDL at the normal content during the early stage of 
atherosclerosis, is very important.
 A lipoprotein-associated phospholipase A2 (Lp-
PLA2) enzyme  which is also called the platelet 
activating factor of asetilhydrolase (PAF-AH) is an 
enzyme produced and secreted by macrophages as a 
response to the lipid peroxide formation, especially the 
PAF compound and phosphocholine peroxide10. In the 
circulation, Lp-PLA2 is bound with apoB of the LDL11.
 Various classical risk factors of atherosclerosis are 
positively correlated with the content of Lp-PLA2 
plasma, such as hypercholesterol12, diabetes13,14, 
hypertension15, metabolic syndromme13,16, as well as 
symptomatic carotid atherosclerotic plaque17,18. The 
hypolipidemic drug decreases LP-PLA2 activity and 
concentration19.  Epidemiologic data show that Lp-
PLA2  influences the cardiovascular disease (CVD), 
either at individuals’ hypercholesterol and normal 
cholesterol20,21 levels, yet its role and correlation with 
various risks factors and critical value of atherogenic 
Lp-PLA2 at the preliminary level have not been further 
studied.
 Atherosclerosis is a chronic inflammation with 
lipid deposits in inflammatory cells, involving oxidative 
stress and endothelial dysfunction. The oxidized LDL 
(oxLDL) is a substrate of the Lp-PLA2 enzyme. As 
the Lp-PLA2 substrate, oxLDL can stimulate the 
expression and secretion of Lp-PLA211,22 so that Lp-
PLA2 is also classified as an oxidative stress marker23. 
Malonyl dialdehyde (MDA) and F2-Isoprostan (F2-
Isp) are known as common markers of oxidative stress 
because they are not only generated from arachidonic 
acid metabolism through the cyclooxygenase pathway, 
but also act as a lipid peroxide of linoleic acid and 
docohexanoic acid24. MDA and F2-Isp can be found in 
tissues as well as in plasma. F2-isoprostan is the best in 
vivo oxidation marker to date, because it is noninvasive 
and has high specificity25. People with atherosclerosis 
risk factors have shown an increase in F2-Isp include 
hypercholesterolemia26, diabetes25 and hypertension27. 
Like Lp-PLA2, measurements of MDA and F2-Isp levels 
in plasma in advanced atherosclerosis also portrays a 
significant increase26,28,29,30. Observation in rats with 
combination of hyper cholesterol feeding treatment 
and duration of eating reported that Lp-PLA2 aorta 
was not significantly different. However, serum levels of 
Lp-PLA2 indicated significant differences. In addition, 
the rate of serum elevation has occurred earlier than the 
increase in the number of foam cells31.
 Based on previous research results, it is necessary to 
conduct further study on the harmful loops caused by Lp-
PLA2 serum activity in the early stages of atherogenesis, 
depending on the different number of foam cells. This 
present research is intended to observe the changes the 
Lp-PLA2 enzyme contents, lipid profiles, and oxidation 
stress in the serum at the different stages of atherogenesis, 
as shown at the different number of foam cells resulted 
by high lipid diet in different times.
Methods 
Animal Housing. The selected experimental animals in 
this research were male rats (Rattus norvegicus) with the 
age of 6-8 weeks, and the weight of 150-200 grams. The 
rats were obtained from CV. Gamma Scientific Biolab 
Malang. The materials for making hyperlipidemic 
foods were BR1(45%, P.T. Wonokoyo Corporation), 
cholesterol (2%, sigma Aldrich), folic acid (0,2%, sigma 
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Aldrich), lard (7,5%, extracted from fresh pork adipose 
tissue), butter (5%) and wheat flour (22,5%, CV. 
Bogasari). The animals were kept under 12-hour bright 
and 12-hour dark conditions, and foods and drinks 
were given in ad libitum. This research had obtained an 
ethical clearance from the Medical Faculty, Universitas 
Brawijaya, Malang, Indonesia, No. 0313/EC/KEPK-
S3-JK/11/2010).
 Experimental Design. In this research, a Post Test 
Control Group Design was employed. Thirty rats at the 
age of 6-8 weeks with each weight of 150-200  grams 
were divided into 2 groups, where the control group 
were given normal foods (BR1) and the experimental 
one with the hyperlipidemic foods for 2, 8 and 12 
weeks periods (5 rats for each period), in order to obtain 
variations in the atherosclerosis development.  At the end 
of the treatment, the serum of lipid profiles (covering 
the contents of the total cholesterol (TC), Triglycerides 
(TG), Low Density Lipoprotein (LDL), High Density 
Lipoprotein (HDL), Lipoprotein phospholipase A2 
(LpPLA2), F2-Isoprostane (F2-Isp), Malonil Dealdehid 
(MDA) and the number of foam cells (FC) in aorta tissue 
were investigated.  The data on the number of foam 
cells were made in three different levels of atherogenesis, 
namely atherogenesis level 1 (Ath-I), level 2 (Ath-II) 
and level 3 (Ath-III).
 Sample Preparation and Assay Variable in Serum. 
At the end of the treatment, in order to extract the blood 
and blood vessels, the rats were anesthetized. The blood 
sample was taken from the heart, and then centrifuged 
in 3000 rpm for 10 minutes. The serums produced 
were soon kept under the temperature of -20oC before 
being used. The LDL-C content was measured with 
the Fiedwall formula; the MDA with the TBA test 
method were observed using a spectrophotometer 
with the wave length of 530.6 nm. Further, the F2-Isp 
were examined using F2-isoprostant Immunoassay Kit 
(Direct 8-iso-Prostaglandin Fά Enzyme Immunoassay 
Kit, Assay Design with the catalog number of 900-
901). The observation followed the procedures stated in 
the product and was made using a spectrophotometer 
with the wavelength of 405 nm. Lp-PLA2 was measured 
using the Sandwhich Ellisa method, examined with 
Elisa reader at the λ 450 nm by following the procedure 
stated in the product (LpPLA2 Sandwich Elisa Kit 
produced by Cusabio Biotech CO., Ltd., with catalog 
number of CSB-E08320r).
 Preparing the Aorta Tissue and Foam Cells 
Examination.  The aorta blood vessels near the heart 
were cut for 1.5 cm and were washed using PBS, then 
were kept in the freezer at the -20oC to make preparation 
of the fresh frozen section. The frozen aorta were cross-
cut with the thickness of  5 µm using cryo cut. The 
prepared materials were kept at -4oC and then stained 
with RedO and HE Oil.  Examination was made on one 
cycle of the cross-cut aorta using the light microscope 
with the magnification of 40x10.
 Statistical Analysis. A one way ANOVA test was 
employed to test the effects of the atherogenesis levels 
on all variables in the serums (the contents of TC, TG, 
LDL, HDL, F2-Isp, MDA and Lp-PLA2). A Least 
Significant Difference (LSD) test was exercised to know 
the pair-wise comparison of the treatment’s mean with 
or without significant difference. The ANOVA and LSD 
tests were done using SPSS 16.0 computation software.
Table 1. Lipid  Profiles in the Rat’s Blood Serums at Various Stages of Atherogenesis 
Stages of  atherogenesis, 







Ath-I 125.11±20.77 110.44±19.26 74.33±21.03 28.33±5.33
Ath-II 148.19±29.49 121.10±16.76 97.25±27.82 26.75±3.29
Ath-III 158.40±32.84 128.60±18.99 106.88±28.39 25.80±2.05
Anova test p>0.05 p>0.05 p>0.05 p>0.05
LSD test
Ath-I vs Ath-II p>0.05 p>0.05 p<0.05 p>0.05
Ath-I vs Ath-III p<0.05 p>0.05 p<0.05 p>0.05
Ath-II vs Ath III p>0.05 p>0.05 p>0.05 p>0.05
non-significant (p>0.05); significant (p<0.05); very-significant (p<0.01) 
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Results
The content of Lipid profile, oxidation level of 
LpPLA2 serum enzyme at different atherogenic 
levels
The number of foam cells observed in the frozen slices 
of blood vessels in a full circle has a range between 
2-146 foam cells. From these data, three different levels 
of atherogenesis were identified, they were categorized 
into level 1 (Ath-I, less than 50 foam cells, 17.33±11.22 
cells), level 2 (Ath-II, between 50 to less than 100 foam 
cells, 68.00±13.64 cells) and level 3 (Ath-III, more than 
100 foam cells, 124.2±18.50 cells). The ANOVA test 
results showed that the number of foam cells at the 
three levels of atherosclerosis differed very significantly 
(p< 0.01), as well as the results of all mean comparisons 
at the three levels of atherosclerosis using the LSD test.
 One way ANOVA and LSD test results showed 
that all TC, TG and HDL lipid profile contents did 
not show any significant difference (p<0.05) among 
the three levels of atherogenesis. While the results of 
statistical tests on LDL levels showed that, even though 
the ANOVA test results did not show a significant 
difference, however LSD test showed that Ath-I was 
significantly different (p<0.05) from the others (Table 
1).  One way ANOVA and LSD test also did not 
identify differences in oxidation stress levels on MDA 
or F2-Isp parameters (p>0.05) among the three levels of 
atherogenesis. ANOVA test of LpPLA2 level in serum 
projected a very significant difference (p<0.01). It was 
in accordance with the LSD test results that displayed a 
significant difference between the contents of Lp-PLA2 
Table 2. F2-Isp, MDA and of Lp-PLA2 Profiles in the Rat’s Blood Serum at Various Stages of Atherogenesis 
Stages of
atherogenesis, Cells/ field of 
view)
Mean Content  of the F2-Isp 
Serum ± STDEV (ng/mL)
Mean Content  of MDA Serum ± 
STDEV (ng/mL)
Mean Content of Lp-PLA2 
Serum ± STDEV (ng/mL)
Ath-I 172.38 ±38.19  2.388 ± 0.512 158.81 ± 50.10 
Ath-II 188.98 ± 45.02 2.756 ± 1.567 212.28 ± 44.43 
Ath-III 218.15 ± 33.37 3.618 ± 2.052 255.14 ± 28.03 
Anova Test p>0.05 p>0.05 p<0.01
LSD Test
Ath-I vs Ath-II p>0.05 p>0.05 p<0.01
Ath-I vs Ath-III p>0.05 p>0.05 p<0.01
Ath-II vs Ath III p>0.05 p>0.05 p>0.05
non-significant (p>0.05); significant (p<0.05); very-significant (p<0.01) 
in the Ath-I, and those of Ath-II and Ath-III. However, 
no significant difference occurred between Ath-II and of 
Ath-III (Table 2).
Discussion
The three levels of atherogenesis in this study showed 
no significant difference in lipid profiles. This was due 
to the fact that these three stages are the early stages of 
atherogenesis. However, the three levels of atherogenesis 
show a tendency that there is an increase in lipid profile 
of TC, TG and LDL. The LSD test results projected 
that the LDL content in Ath-III was significantly higher 
than Ath-I and Ath-II.  The HDL content inclined to 
be inversely proportional to the levels of atherogenesis. 
This is also the case of oxidative stress levels indicated 
by the tendency of elevated levels of F2-Isp and MDA 
along with the increased levels of atherogenesis in blood 
vessels. 
It cannot be denied that the material deposited in 
blood vessel walls in foam cells and atheroslerotic 
plaque in individuals with normal cholesterol or 
hypercholesterolemia are cholesterol molecules. 
Therefore, it can be ascertained that this is another factor 
which increases the cholesterol reactivity in the blood 
circulation so as to trigger an atherogenic inflammatory 
reaction even if the contents are normal. Among the 
parameters, only Lp-PLA2 serum content that has 
shown significant difference since the initial stage and 
the content up to stage of Ath-II has been stabilized 
in this study. The content of Lp-PLA2  in the serum 
of  212.28 ± 44.43ng/ml (Ath-II) has been identified 
significantly different from that of the Ath-I (158.81 ± 
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50.10 ng/ml) and it increased at the Ath-III (255.14 
± 28.03).  This condition due to the possibility of the 
Lp-PLA2 enzyme activity which was able to improve 
the characteristic of the atherogenecity of the LDL 
cholesterol so that it is deposited at the blood vessel 
walls even though the cholesterol content in the serum 
was still at the normal category. 
 A high increase was found in the content of Lp-PLA2 
serum above 200 ng/ml at Ath-II in the observation of 
atherogenesis and a relatively stable increase and then a 
slowly increase at the next period though the addition in 
the content was not significantly different. At the Ath-
III period, it was projected that the content has been 
able to push ahead a significant level of atherogenesis. It 
might be that the content of Lp-PLA2 would rise to the 
next level of atherogenesis to reach its maximal content. 
A similar phenomenon also happened to the research by 
Shi et al. using experimental animal pigs with diabetes/
hypercholesterol11. The content of Lp-PLA2 serum in 
the research had increased sharply since the observation 
at the fourth week and was still high without any 
significant increase at the observations from the 12th to 
the 24th weeks.
 In regards to the materials deposited either in the 
foam cells or atherosclerotic plaques that were LDL, the 
increase of the differences in the number of foam cells 
occurred more rapidly than the increase in the LDL. 
The Lp-PLA2 as a lipase enzyme plays a functionally 
important role in the process of atherogenesis as it is 
closely related to LDL. 
 Lp-PLA2 levels correlated with LDL levels and both 
correlated with the number of foam cells either directly 
or indirectly. Thus, it is predictable that the enzyme of 
Lp-PLA2 becomes the key molecule for the process of 
aterogenesis carrier of LDL accumulation in the foam 
cell. This condition also in line with Goncalves’s et.al’s 
finding, suggesting that the Lp-PLA2 level is significantly 
determinative in correlation with LysoPC levels as well 
as inflammatory cytokine32. The results of this study 
indicated no correlation between formation of foam 
cells with both oxidation stress markers; MDA and F2-
Isp. The findings suggested that oxidative stress acted 
not directly on foam cells formation, but depended on 
LpPLA2 enzyme activity. This is consistent with the 
finding of Stafforini’s et.al that showed the release of F2-
Isp from esterified phospholipids that was also catalyzed 
by both intracellular and plasma Lp-PLA233.
Figure 1. Three Dangerous Proatherogenic Loops caused by Lp-PLA2 Enzyme
Notes: 
LDL: Low Density Lipoprotein, Lp-PLA2: Lipoprotein-Associated Phospholipase A2, LDL-Lp-PLA2: Complex LDL-Lp-
PLA2. oxLDL-Lp- PLA2: Complex LDL-Lp-PLA2 Oxidized, LysoPC: Lyso Phosphatidylcholin, oxFA: Oxidized Fatty Acid, 
oxLDL: Oxidized Low Density Lipoprotein, oxPC: Oxidized-Phosphatidylcholine, ROS: Radical Oxygen Species, SMC: 
Smooth Muscle Cell
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 The potential of Lp-PLA2 as the promoter of LDL 
atherogenesis was not only supported by this research 
results, but also by various other researches. If observed 
in detail, Lp-PLA2 showed its role in the whole process 
of atherogenesis that might cause the three dangerous 
pro-atherogenic loops (Figure 1). 
 Phosphatydilcholine (PC) is a main phospholipid, 
the composer of cell membrane and LDL34. Oxidation 
by free radicals to oxLDL results in oxPC that becomes 
the substrate of the Lp-PLA2 enzyme activities. Lp-
PLA2 is bound to be apoB of LDL11 (Shi et al. 2007), 
hydrolyzing an oxPC to produce LisoPC and oxFA21,35. 
In an analogy of a production machine and the foam 
cells as the product of atherogenesis, Lyso-PC causes the 
formation of three dangerous proatherogenic loops that 
may be categorized into 3 loops:
Loop 1. The activator of the atherogenesis process 
(positive feedback of Lp-PLA2 production)
 LysoPC induced the macrophages so that it 
produced inflamatory cytocin of TNF-α, IL-6 and IL-
1β, playing the role as an autocrine as well as stimulating 
macrophages to produce Lp-PLA2 11,32.
Loop 2. The operator of the atherogenesis process 
(Positive feedback of proatherogenic inflammatory 
reaction)
 LysoPC stimulated the endothel to excrete its 
adhesive molecules21,36,37 which then facilitated the 
migrate of monocytes from the circulation to sub-
endothel, assisting the development  of monicytes into 
macrophages and foam cells11.
Loop 3. The generator of the atherogenesis process 
(positive feedback of ROS production).
 In addition to its role as the source of Lp-PLA2, 
macrophages also acted as potential sources of ROS 
so that the formation reaction of oxLDL and oxPC as 
the substrate of Lp-PLA2 might produce lysoPC as the 
derivative actor for the Proatherogenic to continually 
occur. LysoPC also stimulated SMC of blood vessel 
walls to produce ROS37. The three loops above 
have facilitated the occurrence of LDL oxidation, 
inflammation reaction, ROS formation and provision 
of Lp-PLA2 enzyme which all are keys to form foam 
cells and to support atherogenesis to continue to happen 
although the LDL content was at the normal level.
Conclussion
Studies have shown that the presence of the Lp-PLA2 
serum can be used as a basis to explain the presence 
of CVD patients with normal cholesterol but with 
increasing Lp-PLA2 enzyme. The presence of Lp-PLA2 
significantly improves proatherogenic characteristic of 
LDL. The serum content of Lp-PLA2 for more than 
200ng/ml is a critical content that can improve the 
atherogenic characteristic of LDL. The increased levels 
of Lp-PLA2 has caused an increased atherogenecity 
of LDL, due to the increased inflammation, stress 
oxidation and elevated levels of Lp-PLA2, which act as 
the proatherogenic factors.
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HDL: High Density Lipoprotein
PAF-AH: platelet activating factor of asetilhydrolase
LDL: Low Density Lipoprotein
Lp-PLA2: lipoprotein-associated phospholipase A2
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MDA: Malonyl Dialdehyde
nLDL: native Low Density Lipoprotein
oxLDL: Oxidized Low Density Lipoprotein
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